Once again, in San Diego, the ASH meeting served as a pivotal platform for unveiling crucial updates in multiple myeloma (MM). Among the noteworthy highlights were advancements in various new therapeutic approaches, including bispecific antibodies (BsAbs), CAR-T cell therapy, new insights in the treatment of smoldering MM as well as newly diagnosed MM (NDMM), and finally emerging new treatments.

(BELG J HEMATOL 2024;15(1):4–8)